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Introduction
Arsenic (As), particularly inorganic arsenic 
acid (iAsV), is a ubiquitous contaminant, a 
non threshold class 1 carcinogen (Cantor and 
Lubin 2007; Mandal and Suzuki 2002). Global 
impacts of geogenic As increase the risk for 
elevated As exposure through the consump­
tion of contaminated drinking water and food 
(Francesconi 2010; Sun et al. 2012). Although 
orally ingested and bioavailable, As was previ­
ously thought to be mainly biotransformed 
in the liver (Watanabe and Hirano 2012); 
however, the literature also suggests that As 
can be converted presystemically during gastro­
intestinal transit (Kubachka et al. 2009a; 
Rowland and Davies 1981; Van de Wiele et al. 
2010). Presystemic As metabolism is defined 
as the occurrence of As speciation changes due 
to physicochemical, enzymatic, or microbial 
metabolic processes in the gut before intestinal 
absorption and eventual bioavailability. Given 
the fact that As toxicity is primarily determined 
by its speciation, incorporating presystemic 
specia tion changes into the risk evaluation 
process is warranted.
Analyses of human urine after iAsV expo­
sure revealed sulfur­containing As metabolites 
such as monomethyl monothioarsonic acid 
(MMMTAV) and dimethyl monothioarsinic 
acid (DMMTAV) (Hansen et al. 2004; Raml 
et al. 2007). Sulfur­containing arsenicals have 
also been detected in the urine and feces of 
experimental animals (Conklin et al. 2006; 
Kubachka et al. 2009b), in water (Fisher et al. 
2007), and in vegetables (Yathavakilla et al. 
2008). In addition, thioarsenicals have been 
produced within the headspace of a reaction 
tube containing a human fecal slurry and arse­
nate (Diaz­Bone et al. 2009). Furthermore, 
significant As thiolation has been observed 
with in vitro digestion of iAsV under gastric 
conditions and with human colon micro­
biota (Van de Wiele et al. 2010). More 
recently, Pinyayev et al. (2011) showed that 
arsenate can be converted into methyl­ and 
thioarsenicals by the anaerobic microbiota 
of the mouse cecum. However, the micro­
bial mechanism of thioarsenical formation 
is not well understood. Moreover, the toxic­
ity profiles remain under discussion (Dopp 
et al. 2010).
Given the importance of sulfate reduc­
tion by sulfate­ reducing bacteria (SRB) in 
the human colon (Ley et al. 2006; Marchesi 
2011), previous studies hypothesized that 
the SRB community in the gut may play an 
important role in the thiolation of arsenicals 
(Conklin et al. 2006; Van de Wiele et al. 
2010). In the present study, we investigated to 
what extent thiolation of methylarsonic acid 
relies on the presence and metabolic activity of 
SRB from the human gut. Our findings sug­
gest an active involvement of sulfate­ reducing 
activity toward the gastrointestinal formation 
of thiolated methylarsenicals.
Materials and Methods
Chemicals, media, and microbial cultures. 
Degassed and ultrapure 18 mΩ water 
[double­ distilled ionized water (DDI); 
Millipore, Bedford, MA, USA)] was used to 
prepare the chromato graphic mobile phase 
and the standard stock solutions. American 
Chemical Society–grade ammonium nitrate 
and ammonium dihydrogen phosphate (Fisher 
Scientific, Pittsburgh, PA, USA) and technical­
grade EDTA, tetra sodium salt dihydrate 
(Fisher Scientific, Fair Lawn, NJ, USA), were 
used in the chromatographic mobile phase. 
Certified stock solutions of monomethyl­
arsonic acid (MMAV) and sodium arsenate 
(Na2HAsO4·7H2O) were purchased from 
Chem Service (West Chester, PA, USA) and 
sodium molybdate (Na2MoO4·2H2O) was 
purchased from Sigma­Aldrich (St. Louis, MO, 
USA). Molybdate is not considered to be a 
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Background: Arsenic (As) toxicity is primarily based on its chemical speciation. Although 
 inorganic and methylated As species are well characterized in terms of metabolism and formation in 
the human body, the origin of thiolated methylarsenicals is still unclear.
oBjectives: We sought to determine whether sulfate- reducing bacteria (SRB) from the human gut 
are actively involved in the thiolation of monomethylarsonic acid (MMAV).
Methods: We incubated human fecal and colon microbiota in a batch incubator and in a dynamic 
gut simulator with a dose of 0.5 mg MMAV in the absence or presence of sodium molybdate, an 
SRB inhibitor. We monitored the conversion of MMAV into monomethyl monothioarsonate 
(MMMTAV) and other As species by high-performance liquid chromatography coupled with induc-
tively coupled plasma mass spectrometry analysis. We monitored the sulfate-reducing activity of the 
SRB by measuring hydrogen sulfide (H2S) production. We used molecular analysis to determine the 
dominant species of SRB responsible for As thiolation.
results: In the absence of sodium molybdate, the SRB activity—primarily derived from 
Desulfovibrio desulfuricans (piger)—was specifically and proportionally correlated (p < 0.01) to 
MMAV conversion into MMMTAV. Inactivating the SRB with molybdate did not result in MMAV 
thiolation; however, we observed that the microbiota from a dynamic gut simulator were capable of 
demethylating 4% of the incubated MMAV into arsenous acid (iAsIII), the trivalent and more toxic 
form of arsenic acid (iAsV).
conclusion: We found that SRB of human gastrointestinal origin, through their ability to 
 produce H2S, were necessary and sufficient to induce As thiolation. The toxicological consequences 
of this microbial As speciation change are not yet clear. However, given the efficient epithelial 
absorption of thiolated methylarsenicals, we conclude that the gut microbiome—and SRB activity 
in  particular—should be incorporated into toxicokinetic analysis carried out after As exposure.
citation: DC.Rubin SS, Alava P, Zekker I, Du Laing G, Van de Wiele T. 2014. Arsenic thiolation 
and the role of sulfate- reducing bacteria from the human intestinal tract. Environ Health Perspect 
122:817–822; http://dx.doi.org/10.1289/ehp.1307759
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bactericidal agent. Rather, it is a bacteriostatic 
agent: This compound merely inhibits the 
metabolic activity, limiting SRB in their growth 
and production of hydrogen sulfide (H2S). 
MMAV and iAsV stock solutions were prepared 
in DDI water at 0.1 g As/L and stored at –4°C.
MMMTAV was synthesized using a 
mixture of MMAV and H2S solutions. In a 
1­mL glass vial, 900 μL of a 40­μg As/mL 
MMAV solution and 100 μL of a saturated 
H2S solution were combined. The mixture 
was left overnight on a mechanical shaker for 
thorough mixing. Progress of the reaction was 
verified by liquid chromatography coupled 
with inductively coupled plasma mass spec­
trometry (LC­ICP­MS). Molecular identity 
of the product was checked by LC­LTQ­
XL­MS [LC coupled with linear ion trap MS] 
and MS/MS (Alava et al. 2012). The MMAV 
and H2S solutions were made as described 
by Alava et al. (2012). Briefly, we prepared 
a 40­μg MMAV/mL solution by combining 
60 μL of a 1,850­μg MMAV/mL solution and 
2.94 mL of a 10% vol/vol formic acid solu­
tion. Preparation of the saturated H2S solution 
was conducted in a 100­mL round­bottom 
flask. One gram of iron(II)sulfide (Harshaw 
Scientific, Cleveland, OH, USA) was supple­
mented with 2 mL of hydrochloric acid along 
with 4 mL of DDI. The mixture started to 
bubble instantly, releasing H2S gas. The H2S 
was bubbled into 15 mL of DDI water until 
the effervescence in the round­bottom flask 
subsided, creating the saturated H2S solution.
The Simulator of the Human Intestinal 
Microbial Ecosystem (SHIME) is a dynamic 
multi compartment simulator of the human 
gastrointestinal tract, mimicking the diges­
tive processes of the stomach, small intestine, 
and ascending, transverse, and descending 
colon. The model has been validated against 
human in vivo conditions both in terms of 
gut microbial composition and metabolic 
activity (i.e., short­chain fatty acid profile) 
(Molly et al. 1994; Possemiers et al. 2006). 
The nutritional medium for the SHIME was 
prepared as described by Boever et al. (2000) 
and enabled the microbial communities of 
the different colon compartments to adapt to 
the nutritional and physicochemical condi­
tions that prevail in the ascending, transverse, 
and descending colon. Briefly, 1 L of SHIME 
medium contained 1 g arabino galactan, 2 g 
pectin, 1 g xylan, 3 g starch, 0.4 g glucose, 3 g 
yeast extract, 1 g pepsin, 4 g mucin, and 0.5 g 
cystein, at pH 7.
Postgate medium C (Grossman and 
Postgate 1953) was used to enrich SRB. It 
consisted of 4.5 g sodium sulfate, 0.5 g potas­
sium dihydrogen phosphate, 0.06 g mag­
nesium sulfate, 1.0 g ammonium chloride, 
0.06 g calcium chloride, 1 g yeast extract, 
0.1 g ascorbic acid, 0.004g ferrous sulfate, 6 g 
sodium lactate, and 0.3 g sodium citrate at 
pH 7.5. Modified Postgate medium C with 
different sulfate concentrations was obtained 
using a 4­fold dilution series in the concentra­
tion range: 0.007, 0.032, 0.125, and 0.5 M of 
sodium sulfate.
A pure culture of Desulfovibrio desulfuricans 
LMG 7529 was purchased from the Belgian 
Co­ordinated Collections Of Micro­organisms 
(BCCM­LGM; http://bccm.belspo.be/index.
php) and was grown in the recommended 
medium 104 (BCCM­LMG). This strain is 
equivalent to ATCC 29577 (http://www.atcc.
org). D. desulfuricans is still considered D. piger 
(Castro et al. 2000).
Batch incubations of enriched, non enriched, 
and pure cultures. A first set of experiments 
was used to check to what extent the in vitro–
cultured gut micro biota from the human 
inoculum was capable of performing iAsV bio­
transformation in a manner similar to some 
of our previous findings (Alava et al. 2012; 
Van de Wiele et al. 2010). Briefly, 2 mL of 
descending colon suspension from the SHIME 
(see below) was anaerobically incubated with 
30 μg iAsV/L for 48 hr and then analyzed for 
its As speciation profile with HPLC­ICP­MS as 
detailed by Van de Wiele et al. (2010).
The second set of experiments was more 
specifically targeted at evaluating the poten­
tial of gut microbiota and SRB to thiolate 
MMAV. We anaerobically incubated 2 mL 
of nonenriched SRB descending colon sus­
pension from the SHIME for 48 hr with 
0.5 mg/L MMAV. To favor SRB enrichment, 
2 mL was sampled from the SHIME descend­
ing colon suspension and anaerobically incu­
bated for 48 hr with 0.5 mg/L MMAV in 
18 mL Postgate medium C. The contribution 
of a reference sulfate­ reducing strain toward 
MMAV (0.5 mg/L) thiolation was assessed 
by incubating 2 mL of a pure culture of 
Desulfovibrio desulfuricans (piger) in 18 mL of 
culture medium 104 (BCCM­LMG).
A third set of experiments was performed 
to test the interindividual variability in 
MMAV thiolation by human fecal microbiota. 
Fecal microbiota from seven different human 
individuals with no history of antibiotic 
treatment in the 6 months before the study 
(De Weirdt et al. 2010) and descending colon 
samples from three different SHIMEs were 
separately incubated with 0.5 mg/L MMAV in 
Postgate medium C.
All incubation experiments with enriched 
and non enriched SRB SHIME descending 
colon samples, human fecal microbiota and 
with D. desulfuricans (piger) were performed 
in the absence or presence of sodium molyb­
date (20 mM), a specific SRB inhibitor. In 
addition, heat­sterilized (120°C) incubations 
were used as an abiotic control. Incubations 
were performed under  anaerobic conditions by 
capping the serum bottles with butyl rubber 
stoppers that are impervious to oxygen and 
subsequently flushing the bottles with nitro­
gen gas for 25 min. Cultures were then incu­
bated at 37°C on a rotary shaker (180 rpm) for 
48 hr. Aliquots of 2 mL/analysis were collected 
at four time points—0, 6, 24, and 48 hr—to 
monitor SRB activity, As speciation changes, 
and the molecular analysis of the microbiota. 
This study was approved by Ghent University’s 
ethical committee and registered by Belgian 
authorities (no. B670201214538).
Continuous incubations in a SHIME. 
Although the former batch experiments were 
conducted under SRB­favoring conditions, 
we performed a SHIME run to verify whether 
MMAV speciation changes, particularly thio­
lation, also occurred under more representa­
tive conditions for the human gut that do not 
favor SRB. Moreover, the SHIME reactor 
also allows addressing  colon­ region–specific 
differences in the MMAV thiolation potential.
The treatment consisted of a daily supple­
mentation of 0.5 mg MMAV/L during 4 days. 
20 mM of sodium molybdate was added on 
the third and fourth days of the SHIME run to 
inhibit SRB activity. Aliquots of 2 mL/analysis 
were collected from the ascending, transverse, 
and descending colon in order to monitor the 
conversion of MMAV as well as SRB activity.
SRB activity analysis and sample prepara-
tion for speciation analysis. SRB activity was 
monitored by measuring H2S production 
using an analytical kit for detection of sulfide 
(Hach, Loveland, CO, USA) in an auto­
mated spectrophotometer (Nanocolor 500D; 
Macherey­Nagel, Düren, Germany) in 1:1 and 
1:2 dilutions with anoxic water. To preserve the 
samples for further As speciation analysis, all 
samples were flash frozen with liquid nitrogen 
upon incubation and subsequently stored at 
–80°C. Before analysis with HPLC­ICP­MS, 
the samples were thawed and dissolved with 
ammonium carbonate (20 mM, pH 9.0) to 
minimize any sulfur– oxygen exchange while 
awaiting analysis (Conklin et al. 2006). Upon 
complete thawing, the sample was vortexed 
and centrifuged for 10 min at 10,400 ×g with 
an Eppendorf 5810R centrifuge (Brinkman 
Instruments, Westburg, NY, USA) to separate 
soluble As species from insoluble As (e.g., As 
sorbed to microbial biomass). The supernatant 
was filtered through a Millex­LCR 0.45 μm 
filter (Millipore) with a Luer­Lok 10­mL 
syringe (Becton, Dickinson and Co., Franklin 
Lakes, NJ, USA).
As speciation analysis by HPLC-ICP-MS. 
As speciation changes, and especially the 
conversion of MMAV into MMMTAV and 
arsenous acid (AsIII), were monitored with 
HPLC­ICP­MS matching the retention 
time and by comparing fragmentation pat­
tern of prepared MMMTAV on electrospray 
 ionization–MS/MS with previously published 
conditions (Van de Wiele et al. 2010), using 
the limits of detection and quantification 
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for the different As species indicated in 
Supplemental Material, Table S1. Briefly, 
2 mL of the supernatant of each incubated 
sample was filtered using a 0.45­μm syringe­
type PVDF (polyvinylidene difluoride) mem­
brane filter, and the filtrate was diluted into 
25 mL using DDI water. This filtrate was 
analyzed for total As content using ICP­MS. 
The same filtrate was used for speciation 
analysis using HPLC and optimized instru­
mental parameters for ICP­MS (PerkinElmer, 
Sunnyvale, CA, USA). Filtrates were diluted 
with the mobile phase and injected into the 
HPLC. We considered the sum of the As 
species in the filtrate observed chromato­
graphically to be the bioaccessible fraction. We 
measured total As concentration in the digest 
filtrates using ICP­OES (ICP–optical emis­
sion spectroscopy) according to Alava et al. 
(2012, 2013). The applicable detection limit 
was 0.5 μg/L.
Molecular analysis. We performed poly­
merase chain reaction and denaturing gradi­
ent gel electro phoresis (PCR­DGGE) to 
obtain a general profile of the microbial com­
munity, used qPCR (quantitative PCR) to 
quantify the SRB (see Supplemental Material, 
Table S2), and created a clone library to iden­
tify the most dominant SRB species in the 
enriched and non enriched SRB incubation 
experiments, as well as Illumina (San Diego, 
CA, USA) sequencing of nonenriched fecal 
samples. DNA extraction was carried out 
using the UltraClean® DNA Isolation Kit fol­
lowing the manufacturer’s instructions (Mo 
Bio Laboratories Inc., Carlsbad, CA, USA). 
PCR­DGGE of the 16S rRNA genes for all 
bacteria were amplified by PCR using the Taq­
Polymerase Kit (Fermentas Inc., Hanover, 
MD, USA) with the general bacterial primers 
P338F and P518R and a GC­clamp of 40 bp 
on the forward primer (Muyzer et al. 1993). 
DGGE was performed using the Bio­Rad D 
gene system (Bio­Rad, Hercules, CA, USA). 
Clustering was based on the densito metric 
curves according to the Pearson correlation 
using BioNumerics software (version 5.1; 
http://www.applied­maths.com). (For the 
clone library, see Supplemental Material, p. 2.) 
Briefly, the PCR amplification of 16S rRNA 
gene fragments was carried out with the uni­
versal primers 63F and 1378R and cloned into 
the pCR®­TOPO® Vector of the TOPO TA 
cloning kit (Invitrogen, Carlsbad, CA, USA). 
The qPCR specific for SRB’s target gene, dsrB 
(dissimilatory sulfite reductase subunit beta; 
the gene for the key enzyme in dissimilatory 
sulfate reduction and phylogenetic marker 
for identification of SRBs) was carried out 
as described by Vermeiren (2011), adapted 
from Spence et al. (2008) (See Supplemental 
Material, Figure S1).
Statistical analysis and sequences. Batch 
incubation experiments of more than four 
groups were conducted in triplicate and 
SHIME run in duplicates. All data were ana­
lyzed using SigmaPlot, version 12.0 (SYSTAT 
Software Inc., San Jose, CA, USA). A one­
way analysis of variance (ANOVA) test was 
performed to investigate intergroup differ­
ences. Two­case groups were covered by a 
t­test. Statistical differences for ANOVA 
and t­tests were significant if p ≤ 0.05, and 
highly significant if p ≤ 0.01. The nucleo­
tide sequences data of the clone library are 
available in the European Molecular Biology 
Laboratory–European Bioinformatics Institute 
public database EMBL­EBI (http://www.
ebi.ac.uk/; accession numbers HG531812 
to HG531931).
Results
In our batch incubation experiments with 
SHIME descending colon microbiota, the 
human gut microbiota actively metabolized 
iAsV (30 μg = 100%) (Table 1). Importantly, 
7% MMMTAV formation was observed upon 
48 hr of incubation. In addition, iAsV was 
reduced to AsIII (18%), and further trans­
formation toward monomethyl arsonous 
acid (MMAIII) (6.6%), MMAV (3.2%), and 
dimethylarsinic acid (DMAV) (54%) was 
noted. These data show that the in vitro cul­
tured microbial community from the human 
inoculum in these experiments had the 
potency to actively metabolize iAsV (Table 1).
Subsequently, we investigated to what 
extent SRB are involved in the thiolation of 
MMAV toward MMMTAV. The batch incu­
bations showed that SRB can be enriched with 
Postgate medium C and can be inhibited by 
the addition of sodium molybdate, and this 
was reflected in the sulfide production poten­
tial (Figure 1A). Molybdate is a well­known 
inhibitor of ATP­sulfurylase, thereby inhibit­
ing SRB in their ability to produce sulfide but 
also limiting their ability to generate energy: 
Growth will therefore be reduced (Figure 1; 
see also Supplemental Material, Figure S1). 
Furthermore, we found that descending colon 
microbiota under enriched SRB conditions 
produced significantly more MMMTAV 
(28 μg/L) than under non enriched conditions 
(15 μg/L) (p < 0.01). In contrast, no MMAV 
to MMMTAV conversion was observed when 
the SRB­inhibitor sodium molybdate was sup­
plemented (Figure 1B). In addition, both the 
incubations, with enriched and nonenriched 
SRB cultures, displayed a positive correlation 
(coefficient of determination) between the 
formation of MMMTAV and production of 
H2S (R2 = 0.978 and R2 = 0.992, respectively). 
Finally, no speciation changes were observed 
in the abiotic control, in which heat­sterilized 
colon microbiota were incubated. However, 
the fraction of MMAV remaining in the super­
natant declined because of sorption to the dead 
organic biomass (see Supplemental Material, 
Table S3). This sorption shows the necessity 
of the contribution of sulfate­ reducing activity 
to the thiolation process, whereas inactivation 
through a specific inhibitor or heat­ sterilization 
removes the thiolation  ability. It must be noted 
that the presence of H2S as such suffices to 
chemically produce MMMTAV from MMAV 
(see “Materials and Methods”). Hence, the As 
thiolation in the gut can be considered a chemi­
cal process that requires a biological trigger, 
that is, sulfide production by metabolically 
active SRB.
Table 1. Metabolic potency of colon microbiota (percent toward iAsV speciation from a single experiment).
Time (hr) AsV AsIII MMAV MMAIII MMMTAV DMAV DMAIII
0 100.0a — — — — — —
5 5.1 32.1 3.9 — — 50.1 —
8 4.9 31.2 3.7 3.7 1.2 59.8 —
24 6.7 18.1 5.6 4.7 3.4 64.5 —
48 6.1 18.2 3.2 6.6 7.0 54.3 —
Abbreviations: DMAIII, dimethylarsinous acid; DMAV, dimethylarsinic acid; MMAIII, monomethyl arsonous acid.
aAsV standard at high concentration of 30 μg (100%).
Figure 1. Sulfate- reducing activity (H2S production) (A) and MMMTAV formation (B) in enriched SRB (with 
and without sodium molybdate, the SRB inhibitor), non enriched SRB, and abiotic (sterilized) cultures 
during 48 hr of incubation with MMAV (0.5 mg/L).
*p < 0.05, and **p < 0.01, by one-way ANOVA. #p < 0.05, and ##p < 0.01, by two-case t-test based on non enriched SRB 
(intermediary group).
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To identify the dominant microbial species 
in enriched SRB cultures responsible for the 
thiolation of MMAV, we performed molecular 
analysis using the enriched and non enriched 
SRB cultures. Analysis from the clone library 
revealed a dominant sequence over time (from 
18% to 63% at 6 hr to 48 hr, respectively) 
with 99% of similarity to D. desulfuricans 
(piger) (Figure 2A). PCR­DGGE also 
showed an SRB­predominant band over the 
time observed in the enriched cultures (see 
Supplemental Material, Figures S2 and S3). 
Quantitative analysis with qPCR further con­
firmed the increasing abundance of SRB in 
the enriched cultures (Figure 2B). In addition, 
Illumina sequencing of non enriched fecal incu­
bations showed that D. desulfuricans (piger) is 
the most dominant SRB present in human gut 
(data not shown). Incubations of pure cultures 
of D. desulfuricans (piger) displayed sulfate­
reducing activity and As­thiolation ability 
similar to that observed with the enriched SRB 
colon microbiota (see Supplemental Material, 
Figure S4).
Using SHIME as a dynamic simulator of 
the human gut (see Supplemental Material, 
Figure S5), we then investigated whether thio­
lation of 0.5­mg/L MMAV is colon­region–
specific under more representative conditions 
for the gastrointestinal tract (Figure 3). MMAV 
thiolation was observed in the SHIME, with 
MMMTAV formation primarily taking 
place in the ascending and transverse colon 
compartments at a rate of > 30 μg/L per day 
(Figure 3A,B). This resulted in high amounts 
of MMMTAV (> 35 μg/L) in the ascending 
and transverse colon vessels, whereas only a 
minor amount was observed in the descending 
colon (Figure 3C). MMMTAV formation took 
place within the first 10 hr upon supplementa­
tion of MMAV (Figure 3). Adding sodium 
molybdate on the third and fourth days of 
the SHIME run to eliminate SRB activity did 
not result in a decrease in MMAV conversion. 
Instead of MMMTAV formation, demethyla­
tion of MMAV occurred toward iAsIII (arse­
nous acid)—a process that primarily occurred 
in the distal colon regions (Figure 3C). (For 
information on the SHIME reactor distal 
colon regions and a scheme of As speciation, 
see Supplemental Material, Figures S5 and S6.)
Figure 2. Molecular analysis of SRB cultures. (A) Clone library of 16S rRNA at the genus level (the operational taxonomic unit at 0.03%) during the enrichments of 
SRB culture in Postgate medium C. (B) Relative number of copies normalized to SRB dsrB gene of enriched, non enriched, and pure fecal samples during 48-hr of 
incubation. Values are mean ± SD; n = 3.
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Finally, we observed interindividual vari­
ability in the sulfate­ reducing activity and 
MMAV thiolation between different human 
fecal inocula (Figure 4). The fecal microbiota 
from individuals A and C displayed much 
higher levels of H2S (> 15 mg/L H2S) in 
comparison with the fecal microbiota from 
the other individuals (Figure 4A). This H2S 
production from fecal microbiota A and C 
corresponded with a pronounced production 
of MMMTAV (> 20 μg/L) (Figure 4B). In 
contrast, for those fecal microbiota that dis­
played low SRB activity (around 5 mg/L H2S), 
only a limited amount of MMMTAV was 
formed over time (around 4.5 μg/L at 24 and 
48 hr). Moreover, the fecal microbial inocu­
lum G displayed the lowest H2S production 
(< 2.5 mg/L) and no formation of MMMTAV. 
Overall, MMMTAV formation and H2S pro­
duction by fecal microbiota from each of the 
individuals were strongly correlated to one 
another (R2 = 0.994) after 48 hr.
Discussion
The findings of the present study show that 
human colon micro organisms have the 
potency of pre systemic As metabolism, simi­
lar to results previously obtained with rodent 
(Conklin et al. 2006; Kubachka et al. 2009a) 
and human gut microbiota (Van de Wiele et al. 
2010). Moreover, this study shows that the 
active involvement of SRB from human origin 
contributes to the thiolation of MMAV into 
MMMTAV. We observed this process both in 
enriched and nonenriched SRB in cultures of 
the descending colon, of human fecal micro­
biota, and of pure SRB isolates, as well as under 
more representative conditions for the human 
gut in the SHIME, a dynamic gut simulator. 
The active contribution of SRB was demon­
strated by the high correlation between H2S 
production and MMMTAV formation and by 
the lack of MMMTAV formation and H2S 
production in the presence of the SRB inhibi­
tor sodium molybdate. Moreover, our findings 
indicate that D. desulfuricans (piger) may be the 
principal microbe contributing to the As thiola­
tion process. Although the metabolic activity of 
SRB has been well studied and even implicated 
in the methylation process of mercury 
(Gilmour et al. 2011), the role of metabolically 
active SRB, and particularly D. desulfuricans 
(piger), toward As thiolation is a new finding.
Our observations parallel those of studies 
showing MMMTAV formation upon incu­
bation of iAsV with human colon microbiota 
(Van de Wiele et al. 2010) or the formation of 
headspace thio­arsenicals when a human fecal 
slurry was incubated with arsenate (Diaz­Bone 
et al. 2009). Previous studies have reported that 
mouse cecal microbiota can trigger the forma­
tion of thioarseno sugars upon the incubation 
with arsenosugars (Conklin et al. 2006) as well 
as the production of methylated thioarsenicals 
from DMAV by rat intestinal microbiota 
(Yoshida et al. 2001) and DMAV conversion 
into trimethylarsine sulfide by mouse ceca 
(Kubachka et al. 2009a). Therefore, the pres­
ence of SRB in both the human and different 
animal gastrointestinal environments may be 
considered to be an important factor in the As 
thiolation process and, when considering the 
environmental presence of SRB, to also impact 
the biogeo chemical cycles of sulfur and As 
(Muyzer and Stams 2008). Yet, As thiolation 
involves a chemical reaction that is biologically 
induced by metabolically active SRB. This view 
is supported by the possibility of chemically 
producing MMMTAV by reacting MMAV 
with a saturated H2S solution and corresponds 
with previous hypotheses that the presence of 
sulfide is sufficient to obtain interconversion 
between oxide and sulfide forms of MMAV, 
DMAV, and trimethyl arsine oxide (Conklin 
et al. 2006).
Although the importance of As thiolation 
by endogenous SRB can be derived from the 
present data set, the results also demonstrate 
that the thiolation does not take place at 
the same rate throughout the entire gastro­
intestinal tract. In the present study, As thio­
lation appeared to be colon­region specific: 
Thiolation primarily occurred in the ascend­
ing and transverse colon. This observation 
is strongly supported by the fact that in the 
in vivo human colon, SRB are more abundant 
in the ascending and transverse colon, whereas 
homo­acetogens (which compete for reducing 
equivalents) are more abundant than SRB in 
the descending colon (Nava et al. 2012).
In addition, the inactivation of SRB activ­
ity by sodium molybdate in the SHIME colon 
compartments resulted in the demethyla­
tion of MMAV toward iAsIII by descending 
colon microbiota. Although demethyla tion 
of MMAV was previously reported for soil 
microbial communities (Yoshinaga et al. 
2011), this is to our knowledge the first 
study to report As demethyla tion by human 
colon micro organisms. These findings are 
of toxicological concern. On the one hand, 
MMAV demethyla tion is rather unexpected 
Figure 3. As speciation of MMAV into MMMTAV and AsIII in the ascending (A), transverse (B), and descending (C) colon of the dynamic gut model SHIME. As 
speciation (i.e., thiolation of MMAV into MMMTAV or demethylation of MMAV into AsIII), was measured daily during 4 days (the 24, 25, 26, 27th days) at two time 
points: 10 and 16 hr. The horizontal arrows indicate the sequence of colon compartments of the SHIME. The vertical arrow in (A) indicates the addition of the SRB 
inhibitor sodium molybdate.
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Figure 4. Interindividual variability of sulfate- reducing activity (H2S production; A) and thiolation 
(MMMTAV formation; B) in different human fecal samples (from individuals A, B, C, G, H, I, and J) during 
48 hr of incubation with MMAV. Abiotic controls are represented by the heat sterilized incubation of fecal 
microbiota from individual A.
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because iAsIII is more toxic than MMAV 
(Naranmandura et al. 2011; Van de Wiele 
et al. 2010). On the other hand, the strongly 
reducing conditions that prevail in the SHIME 
colon compartments (–200 to –250 mV) may 
lead to the reduction of MMAV toward its 
trivalent analogue, MMAIII. The ability of this 
As species to generate highly reactive oxygen 
species and to induce DNA damage makes 
it an order of magnitude more toxic than 
iAsIII (Naranmandura et al. 2011). Although 
MMAIII was not detected under the dynamic 
incubation conditions of the SHIME, its 
production as intermediate is likely, as was 
also indicated by the finding of considerable 
amounts of MMAIII upon static incubation 
of iAsV (Table 1). Supported by reports that 
MMMTAV is several orders of magnitude 
less toxic than iAsIII, and even less toxic than 
iAsV, we therefore consider intestinal MMAV 
thiolation to be a detoxification reaction; how­
ever, further investigation is needed. Thiolated 
arsenicals display a highly variable toxicity 
profile. The monothiolated form of DMAV, 
DMMTAV—often found in the urine of 
iAsV­exposed individuals (Heitland and Köster 
2008; Raml et al. 2007)—is one of the most 
toxic As species known, comparable to DMAIII 
(dimethylarsinous acid), whereas its dithiolated 
analogue, DMDTAV (dimethyldithioarsinic), 
is almost harmless (Naranmandura et al. 
2011). Whether SRB also contribute to the 
formation of DMMTAV, just as they do for 
MMMTAV, remains to be resolved.
Finally, As thiolation was characterized 
by a large interindividual variability. Again, 
the ability for a fecal microbiome to produce 
MMMTAV correlated with the levels of H2S 
produced, further supporting the role for SRB 
as the basis of the thiolation process. Despite 
the enterotypes (Arumugam et al. 2011), the 
human gut microbiome is known for its high 
interindividual variability, which might also be 
reflected in the variable abundance of SRB in 
the colon lumen or on the colon mucosal sur­
faces (Nava et al. 2012). Although host genetic 
factors have been reported to contribute to 
the interindividual variability in As toxicity 
(Hernández and Marcos 2008), we propose 
that the gut microbiome must be incorporated 
as a factor that contributes to this variability.
Conclusion
From the findings presented here, we conclude 
that gut microbiota of human origin can exten­
sively metabolize As, with SRB being neces­
sary and sufficient for the biologically induced 
thiolation of MMAV into MMMTAV. The 
variability in the thiolation potency between 
different fecal inocula was reflected by a large 
interindividual variability in SRB abundance. 
In addition, eliminating SRB activity (as evi­
denced by H2S production) may also result 
in MMAV demethylation to iAsIII. Although 
the toxicological consequences of these micro­
bial processes are not yet clear and the inter­
individual variability adds an extra layer of 
complexity over As toxicokinetics, our find­
ings demonstrate the necessity to consider SRB 
and, by extension, the human gut microbiome 
when assessing risks from oral As exposure.
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